List of Vumerity drug patents
Vumerity is owned by Biogen Inc.
Vumerity contains Diroximel Fumarate.
Vumerity has a total of 3 drug patents out of which 0 drug patents have expired.
Vumerity was authorised for market use on 29 October, 2019.
Vumerity is available in capsule, delayed release;oral dosage forms.
Vumerity can be used as method of treating multiple sclerosis.
The generics of Vumerity are possible to be released after 20 September, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(10 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic